Akademiska Hus AB Publication of Suppl.Prospcts

RNS Number : 3829C

Akademiska Hus AB

07 February 2024

 

SUPPLEMENTARY PROSPECTUS DATED 7 FEBRUARY 2024 TO THE PROSPECTUS DATED 25 MAY 2023

 

AKADEMISKA HUS AB (publ)

(incorporated as a limited company in the Kingdom of Sweden with registered no. 556459-9156)

 

€4,000,000,000

 

Euro Medium Term Note Programme

 

This Supplement (the "Supplement") to the Prospectus dated 25 May 2023 as supplemented by the supplements dated 12 July 2023 and 25 October 2023 (as so supplemented, the "Prospectus"), which comprises a base prospectus, constitutes a supplementary prospectus for the purposes of Section 87G of the Financial Services and Markets Act 2000 (the "FSMA") and is prepared in connection with the €4,000,000,000 Euro Medium Term Note Programme (the "Programme") established by Akademiska Hus AB (publ) (the "Issuer").

 

Terms defined in the Prospectus have the same meaning when used in this Supplement. This Supplement is supplemental to, and should be read in conjunction with, the Prospectus.

 

The Issuer accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Issuer the information contained in this Supplement is in accordance with the facts and the Supplement makes no omission likely to affect the import of such information.

 

Purpose of the Supplement

 

The purpose of this Supplement is (a) to incorporate by reference the Issuer's Year End Report for 1 January 2023 to 31 December 2023 (the "Year End Report") and (b) to update the significant change statement set out in the Prospectus.

 

Year End Report for 1 January 2023 to 31 December 2023

 

On 6 February 2024, the Issuer published its Year End Report which contains its unaudited consolidated annual financial statements as at and for the twelve-month period ended 31 December 2023, available at https://www.akademiskahus.se/globalassets/dokument/ekonomi/ekonomiska-rapporter/year-end-report-q4-2023_eng.pdf. A copy of the Year End Report has been filed with the Financial Conduct Authority and, by virtue of this Supplement, is incorporated by reference in, and forms part of, the Prospectus.

 

If documents which are incorporated by reference themselves incorporate any information or other documents by reference therein, either expressly or implicitly, such information or other documents will not form part of this Supplement for the purposes of the Prospectus Regulation (Regulation (EU) 2017/1129) as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 except where such information or other documents are stated within this Supplement as specifically being incorporated by reference.

 

General Information

 

There has been no significant change in the financial performance or financial position of the Issuer or of the Group since 31 December 2023 (being the date of the Issuer's last published financial statements).

 

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the Prospectus by this Supplement and (b) any other statement in or incorporated by reference in the Prospectus, the statements in (a) above will prevail.

 

Save as disclosed in this Supplement, no other significant new factor, material mistake or material inaccuracy relating to information included in the Prospectus has arisen or been noted, as the case may be, since the publication of the Prospectus.

http://www.rns-pdf.londonstockexchange.com/rns/3829C_1-2024-2-7.pdf

  http://www.rns-pdf.londonstockexchange.com/rns/3829C_2-2024-2-7.pdf

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

PSPBSGDDSSGDGSR